Use of convalescent plasma therapy in SARS patients in Hong Kong
By Yunfeng Cheng, R. Wong, Y. Soo, W. Wong, C. K. Lee, M. Ng, P. Chan, K. Wong, C. Leung, G. Cheng. European Journal of Clinical Microbiology and Infectious Diseases, 2004
937 citations recorded by the source corpus.
In order to evaluate the efficacy of convalescent plasma therapy in the treatment of patients with severe acute respiratory syndrome (SARS), 80 SARS patients were given convalescent plasma at Prince of Wales Hospital, Hong Kong, between 20 March and 26 May 2003. Good outcome was defined as discharge by day 22 following the onset of SARS symptoms. Poor outcome was defined as death or hospitalization beyond 22 days. A higher day-22 discharge rate was observed among patients who were given convalescent plasma before day 14 of illness (58.3% vs 15.6%; P<0.001) and among those who were PCR positive and seronegative for coronavirus at the time of plasma infusion (66.7% vs 20%; P=0.001).
Subfields: Infectious Diseases, Obstetrics and Gynecology
View Paper: https://www.semanticscholar.org/paper/79394af107ef431da927578153a14ce7d29d22e1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Obstetrics and Gynecology
Citations in the corpus
- COVID-19: immunopathogenesis and Immunotherapeutics (2020, background): “demonstrated that it is more effective to administer convalescent plasma during early stages of the disease.(66) However, despite potentially rapid availability, the deployment of convalescent plasma will be limited because transfusions are typically performed in hospital settings and may require la”
- Deployment of convalescent plasma for the prevention and treatment of COVID-19. (2020, neutral): “The selected dosing was based on experience with previous use of convalescent plasma therapy in SARS, where 5 mL/kg of plasma at a titer of 1:160 or greater was utilized (16).”
- Coronavirus disease 2019 (COVID-19): current status and future perspectives (2020, neutral): “levels 24 h after plasma transfusion [100-102].”
- Coronavirus Infections in Children Including COVID-19 (2020, background): “[165] [166] [167] [168] [169] [170] [171] A protein, which also inhibits the spike glycoprotein S, although it is not a monoclonal antibody, has been isolated from a red alga called Griffithsia.”
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? (2006, neutral): “Passive antibodies have been used to prevent or treat such diseases as rabies, measles, hepatitis B, cytomegalovirus, and respiratory syncytial virus (6), and convalescent human plasma may have efficacy in the treatment of severe acute respiratory syndrome (7, 8).”
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients (2020, neutral): “01), highlighting the importance of timely rescue therapy (9).”
- COVID-19: Transmission, prevention, and potential therapeutic opportunities (2020, neutral): “Therefore, convalescent plasma is employed as a rapid immune-based therapy in the early stages of the disease [140], to increase infected patients immunity against the virus, stop COVID-19 progression, and enhance the therapeutic success rate [141].”
- Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus (2005, background): “Human convalescent-phase plasma apparently had a beneficial effect if administered early in the course of SARS infection (49).”
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. (2020, background): “Inclusion Criteria Inclusion criteria were the following: (1) signed informed consent; (2) aged at least 18 years; (3) COVID-19 diagnosis based on polymerase chain reaction (PCR) testing; (4) positive PCR result within 72 hours prior to randomization; (5) pneumonia confirmed by chest imaging; (6) cl”